A phase II study of dexamethasone (Decadron), thalidomide (Thalomid), and Lenalidomide (Revlimid) for subjects with relapsed or refractory multiple myeloma.

Trial Profile

A phase II study of dexamethasone (Decadron), thalidomide (Thalomid), and Lenalidomide (Revlimid) for subjects with relapsed or refractory multiple myeloma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2017 Status changed from active, no longer recruiting to discontinued.
    • 09 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top